Document is current
Any future updates will be listed below
-
Authors
Klučková, Tereza
Nikolič, Marek
Tylš, Filip
Viktorin, Vojtěch
Vejmola, Čestmír
Viktorinová, Michaela
Bravermanová, Anna
Androvičová, Renáta
Andrashko, Veronika
Korčák, Jakub
Zach, Peter
Hájková, Kateřina
Kuchař, Martin
Balíková, Marie
Brunovský, Martin
Horáček, Jiří
Páleníček, Tomáš
-
Funding
Funding for this research was provided by:
The Czech Psychedelic Research Foundation
Ministry of Health of the Czech Republic (Long-term conceptual development of Research organization, RVO 00023752)
Ministry of Education Youth and Sports of the Czech Republic (ERDF-Project Brain dynamics, No. CZ.02.01.01/00/22_008/0004643)
Charles University, Czech Republic (research program Cooperatio-Neurosciences)
Czech Health Research Council (project NU21-04-00307)
- License Information
-
More Information
Article History
Received: 12 February 2025
Revised: 19 May 2025
Accepted: 22 May 2025
First Online: 16 June 2025
Declarations
:
: T.P., M.Br., F.T. and J.H. declare to have shares in “Psyon s.r.o.”. T.P., M.Br., F.T. and J.H. founded the “PSYRES—Psychedelic Research Foundation“ and have shares in “Společnost pro podporu neurovědního výzkumu s.r.o”. T.P. and M.K. have shares in AVI-X Aviation Experts s.r.o. T.P. reports consulting fees from GH Research and CB21-Pharma and F.T. and V.V. from Compass Pathways outside the submitted work. T.P., V.V., M.V. and F.T. were/are involved in Compass Pathways, GH-Research, Ketabon and/or MAPS clinical trials with psilocybin/5-MeO-DMT/ketamine/MDMA trials and F.T. in MindMed study with LSD outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
